Rapid Influenza Diagnostic Tests (RIDT) Market Size & Share 2026-2035

Rapid Influenza Diagnostic Tests Market Size

The global rapid influenza diagnostic tests market was estimated at USD 1.5 billion in 2025. The market is expected to grow from USD 1.6 billion in 2026 to USD 2.5 billion in 2035, at a CAGR of 4.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

Rapid influenza diagnostic tests (RIDTs) are immunoassays that detect influenza A and B viral nucleoprotein antigens in respiratory specimens, typically producing qualitative results in less than 15 minutes ^{[1]Centers for Disease Control and Prevention, Rapid Diagnostic Testing for Influenza: Information for Clinical Laboratory Directors, cdc.gov}.

The historical expansion rate of approximately 9.8% between 2022 and 2025 is forecast to moderate as respiratory-testing demand moves beyond pandemic-era normalization. The outlook instead rests on recurrent influenza burden, wider use of point-of-care testing in clinical workflows, and procurement of faster tests where treatment, isolation, or referral decisions cannot wait for centralized laboratory turnaround. Immunochromatographic and lateral-flow formats remain central because they combine short turnaround times with decentralized deployment, while digital immunoassays, multiplex respiratory panels, and point-of-care nucleic-acid amplification tests broaden the performance and workflow options available to providers ^{[2]World Health Organization, Clinical Practice Guidelines for Influenza, 2024, iris.who.int}.

The regulatory environment creates both a floor for product performance and a constraint on product entry. In the United States, RIDTs are Class II devices subject to special controls, including minimum sensitivity and specificity requirements against RT-PCR for influenza A and B detection. Internationally, WHO guidance supports the use of digital immunoassays or nucleic-acid amplification tests in defined clinical settings, particularly where patients have elevated risk of severe disease.

Our primary research with U.S. clinical laboratories indicates that influenza testing remained operationally significant during the 2024–25 season: laboratories tested 3,978,954 respiratory specimens, and 489,579 were positive. Positivity reached its highest weekly peak in nine seasons during the week ending February 1, 2025. Paired with GMI's estimate of a USD 1,484.69 million global market in 2025, this pattern shows why seasonal surges continue to support rapid-test purchasing even as the market's longer-term growth rate normalizes. Suppliers that can combine dependable seasonal availability with performance suited to frontline decision-making should be better placed than suppliers competing only on low unit price.

Key Drivers

Growing prevalence of influenza

Influenza burden creates episodic demand that is concentrated around short seasonal windows, making turnaround time commercially important. During the 2024–25 U.S. season, influenza A represented 88.8% of positive clinical-laboratory tests, and influenza A positivity reached 30.4% in late January 2025 ^{[3]Centers for Disease Control and Prevention, 2025–2026 Influenza Activity (2024–25 Season Summary), cdc.gov}. When positivity rises sharply, providers need a practical means of distinguishing influenza from other respiratory conditions quickly enough to support triage, infection-control, and treatment decisions.

This seasonality favors suppliers able to maintain inventory reliability and support decentralized testing sites. Demand can be volatile by week, but the requirement for accessible testing infrastructure persists across seasons, sustaining baseline demand for RIDTs even when disease intensity recedes.

Technological advancements

Digital immunoassays and point-of-care nucleic-acid amplification tests address a key limitation of conventional visual-read antigen testing: variable performance and interpretation at the point of use. WHO conditionally recommends digital immunoassays or nucleic-acid amplification tests for suspected non-severe influenza and supports point-of-care versions of these technologies for patients at high risk of severe disease ^{[4]World Health Organization, Essential Diagnostics List, Influenza A and B POC testing, SAGE IVD Recommendation No. 168, edl.who-healthtechnologies.org}.

Technology adoption will not displace conventional RIDTs uniformly. In cost-sensitive settings, conventional antigen formats retain relevance because their workflow and infrastructure requirements are limited. Higher-performing digital and molecular formats are more likely to gain traction where clinical risk, throughput, reimbursement, or laboratory-governance requirements justify the additional system cost.

Rising demand for early influenza diagnosis and management

Earlier diagnosis matters most where clinicians must make treatment, isolation, or escalation decisions before confirmatory laboratory results become available. CDC guidance notes that rapid tests can support clinical decision-making, while also emphasizing that negative antigen results should be interpreted in the context of influenza activity and clinical presentation because false-negative results can occur. The resulting market opportunity is therefore not simply a test-volume opportunity; it is a workflow opportunity requiring appropriate test selection and result interpretation.

Testing adoption in emergency care illustrates this shift. U.S. emergency-department influenza testing rose from 2.5% of visits in 2013 to 10.9% in 2022, reaching an estimated 16.99 million weighted visits with influenza testing. This broader testing footprint increases the value of products that fit acute-care workflows and can be deployed with clear escalation pathways for negative or inconclusive results.

Increasing popularity of rapid diagnostic tests

Rapid tests gain relevance as testing moves closer to patients and away from centralized laboratories. WHO's Essential Diagnostics List recommendation supports point-of-care influenza testing across primary care, district hospitals, and secondary and tertiary care settings. That positioning is particularly important in systems seeking to expand respiratory-disease surveillance while reducing referral and turnaround burdens.

The commercial implication is that adoption depends on more than analytical performance. Training, specimen collection, connectivity, procurement packaging, and availability during influenza peaks shape whether a rapid test becomes embedded in routine care. Manufacturers that address those implementation conditions can extend use beyond specialist laboratories.

Key Restraints

Lack of skilled professionals

Rapid testing reduces turnaround time, but it does not eliminate the need for sound specimen collection, quality assurance, and result interpretation. CDC guidance cautions that RIDTs have lower sensitivity than RT-PCR and that a negative result does not necessarily exclude influenza when community activity is high. In sites without trained staff or reliable confirmatory pathways, this limitation can reduce confidence in routine RIDT use.

The constraint is most material where point-of-care testing expands faster than laboratory-management capacity. It may limit the conversion of nominal demand into sustained purchasing, particularly for digital and multiplex platforms that require operator training, internal controls, or integration into clinical documentation.

Stringent regulatory approvals

Regulatory requirements support product quality but extend development and market-entry timelines. FDA Class II special controls require antigen RIDTs to meet performance thresholds of at least 80% sensitivity and 95% specificity against RT-PCR for influenza A and B. Product developers must therefore demonstrate performance across circulating strains, specimen types, and intended-use settings before commercial launch.

The approval burden can reinforce the position of established suppliers with regulatory experience, validation resources, and post-market infrastructure. It can also slow geographic expansion for smaller companies, particularly where products require separate evidence packages or local registration processes across multiple jurisdictions.

The expansion in U.S. emergency-department testing to 10.9% of visits in 2022 demonstrates that influenza testing is becoming more routine in acute-care pathways. At the same time, FDA performance controls and WHO's differentiated recommendations for digital immunoassays and nucleic-acid amplification tests place a premium on matching technology to patient risk and care setting. Companies able to provide a credible pathway from simple screening to higher-confidence follow-up testing should capture more durable demand than companies offering an isolated assay without clinical-workflow support.

Rapid Influenza Diagnostic Tests Market Segment Analysis

By Product Type

Conventional RIDTs remain important because they address settings where affordability, simplicity, and rapid deployment outweigh the need for instrument-based interpretation. Their role is reinforced in decentralized locations that need influenza screening during seasonal peaks but may not have the throughput or capital budget for analyzers.

Digital RIDTs address interpretation consistency and can be more attractive in organized care networks, emergency settings, and facilities with established quality-management processes. The segment's opportunity is therefore linked less to replacing every conventional test and more to upgrading testing points where documentation, standardized interpretation, and clinical confidence carry higher value.

By Technology

Immunochromatographic and lateral-flow assays remain the core rapid-test technologies because they are aligned with the defining RIDT requirement of near-patient results in a short time frame. Their commercial strength lies in accessible workflows, but their performance profile requires appropriate use conditions and clinical interpretation.

PCR and other molecular approaches serve a different portion of the diagnostic pathway. They are relevant where higher analytical confidence, multiplex respiratory testing, or testing of high-risk patients is required. WHO's guidance supports use of point-of-care nucleic-acid amplification tests and digital immunoassays in these circumstances, creating a technology ladder rather than a single-format market.

By Sample Type

Nasal swabs are well aligned with point-of-care testing because collection can be integrated into ambulatory and acute-care intake workflows. Sample collection remains a meaningful determinant of real-world performance, however, since poor collection can weaken the utility of an otherwise appropriate assay.

Throat swabs and other sample types remain relevant where patient tolerance, clinical protocols, or a test's authorized instructions for use support alternative collection methods. Manufacturers must align packaging, instructions, and training materials with the specific specimen claims supported by their regulatory authorization.

By End Use

Diagnostic centers benefit from rapid tests when they need to manage seasonal volume efficiently while retaining access to confirmatory testing. Hospitals use rapid influenza testing in triage and infection-control workflows, particularly when a result can influence isolation, treatment, or admission decisions. The increase in influenza testing across all four U.S. regions and among all age groups in emergency departments indicates that demand is not confined to a narrow institutional setting ^{[5]Centers for Disease Control and Prevention, NCHS, Emergency Department Visits With an Influenza Test Ordered or Provided: United States, 2013–2022, Data Brief No. 517, December 2024, cdc.gov}.

Research laboratories and other end users represent a distinct demand base because their selection criteria may emphasize comparative performance, surveillance needs, or compatibility with broader respiratory-testing workflows. The winning product configuration will therefore differ by end user: low-complexity access matters most in decentralized sites, while performance documentation and integration matter more in institutional networks.

GMI's North American estimates show conventional RIDTs expanding from USD 387.93 million in 2025 to USD 500.42 million by 2035, while digital RIDTs increase from USD 239.50 million to USD 323.15 million over the same period. The parallel growth reflects a segmented market in which accessibility and clinical confidence are both valuable. WHO's differentiated recommendations for digital immunoassays and point-of-care nucleic-acid amplification tests further support this tiered adoption pattern. Suppliers should avoid positioning digital systems as a simple substitute for low-cost antigen formats; the commercial case is strongest where improved interpretation or performance changes the care pathway.

Rapid Influenza Diagnostic Tests Market Regional Analysis

North America

North America represented USD 510.01 million, or 34.35%, of the global market in 2025 and is projected to reach USD 823.57 million by 2035. The United States accounted for USD 479.34 million of the regional total in 2025, while Canada contributed USD 30.66 million. The region's scale reflects established clinical testing pathways, regulatory oversight, and recurring influenza surveillance activity.

U.S. demand is supported by a large testing base and recurring seasonal pressure. Clinical laboratories processed nearly 4.0 million respiratory specimens during the 2024–25 influenza season, while emergency-department testing penetration had already increased materially over the preceding decade. These conditions support use across hospitals, diagnostic centers, and decentralized care sites, while FDA performance controls raise the importance of documented assay quality ^{[6]U.S. Food and Drug Administration, Influenza Diagnostic Tests (In Vitro Diagnostics), updated July 22, 2024, fda.gov}.

Europe

Europe generated USD 414.73 million in 2025 and is projected to reach USD 660.08 million by 2035. Germany, the UK, France, Spain, Italy, and the Netherlands form the principal country markets within the region. Demand is shaped by the need to deploy tests that can function within established primary-care, hospital, and laboratory networks while meeting jurisdiction-specific product-access requirements.

The regional opportunity is likely to favor products with clear clinical positioning. WHO's 2024 guidance differentiates between digital immunoassays and nucleic-acid amplification tests according to disease severity and patient risk, reinforcing the value of portfolio breadth rather than a single product format.

Asia Pacific

Asia Pacific reached USD 376.97 million in 2025 and is projected to expand to USD 666.02 million by 2035. China, Japan, India, Australia, and South Korea are the key country markets. At a projected 5.86% CAGR, the region is expected to outpace the global market and add USD 289.05 million in revenue between 2025 and 2035, exceeding Europe's projected incremental growth over the same period.

The region is also the only major geography expected to record a material share gain, rising from 25.39% of global revenue in 2025 to 27.12% in 2035. WHO's Essential Diagnostics List supports point-of-care influenza tests across primary care, district hospitals, and higher-level facilities. This is relevant to markets where access expansion and procurement through public health systems can widen the use of rapid tests beyond specialist laboratories.

Latin America

Latin America accounted for USD 123.15 million in 2025 and is projected to reach USD 210.50 million by 2035. Brazil, Mexico, and Argentina are the principal country markets. Growth depends on whether health systems can combine access to tests with training, supply continuity, and pathways for managing negative results during periods of elevated influenza activity.

The region's smaller revenue base does not remove the importance of product economics. Conventional formats may remain attractive where decentralization is needed but instrument infrastructure is limited, while digital or molecular systems require a clearer clinical and procurement rationale.

Middle East and Africa

The Middle East and Africa market totaled USD 59.84 million in 2025 and is expected to reach USD 95.89 million by 2035. South Africa, Saudi Arabia, and the UAE are the designated country markets. The region's opportunity is closely tied to surveillance capacity, public-sector procurement, and the ability of providers to embed rapid testing in defined care pathways.

WHO's endorsement of point-of-care influenza testing across multiple levels of care provides a relevant procurement reference for systems seeking to extend diagnostic access. Adoption, however, will remain sensitive to workforce capability and the practical availability of follow-up testing for clinically significant negative results.

Asia Pacific's projected USD 289.05 million incremental revenue opportunity through 2035 is larger than Europe's, and its expected 1.73-percentage-point global share gain is significant in a market otherwise led by established regions. WHO's support for point-of-care influenza testing across primary care and hospital levels provides a policy basis for broader deployment. Commercial success in the region will depend on converting that policy relevance into affordable procurement, operator capability, and reliable seasonal supply; a product designed only for high-resource laboratory settings will not address the full opportunity.

Rapid Influenza Diagnostic Tests Market Share & Competitive Landscape

The RIDT market is characterized by competition across conventional antigen testing, digital interpretation, multiplex respiratory testing, and molecular diagnostic pathways. Product performance alone does not determine market position. Regulatory clearance, distribution reach, seasonal supply reliability, clinical-workflow compatibility, and the ability to support decentralized users are equally important.

The authorized company landscape comprises 3B BlackBio, Abbott, Access Bio, Becton, Dickinson and Company, bioMérieux, CHEMBIO, DiaSorin, Meridian, Quidel Corporation, Roche, SEKISUI, Siemens Healthineers, and Thermo Fisher Scientific. Competition among these companies is likely to remain differentiated by care setting and technology format rather than resolved through a single dominant testing model.

Abbott, BD, and Roche are especially relevant to competitive assessment because their diagnostic portfolios can address distinct points in respiratory-testing workflows. Abbott's rapid-test presence is most relevant where low-complexity deployment and broad access are required. BD's position is linked to institutional diagnostic workflows and the integration of respiratory testing into clinical operations. Roche's strength is most applicable where hospitals and laboratories prioritize platform performance, multiplexing, and connectivity. Across all three, the strategic challenge is to match product complexity and performance to the clinical consequence of the testing decision.

Regulatory barriers can raise the value of established validation and quality systems. FDA special controls for RIDTs require specified sensitivity and specificity thresholds versus RT-PCR, creating a meaningful compliance hurdle for new entrants. Smaller competitors can still compete effectively where they offer a targeted format, local distribution strength, or a commercially viable response to an underserved care setting.

Recent Industry Developments

• In April 2025, the FDA-cleared-device registry recorded clearance for SEKISUI Acucy® under submission K241188.

• In July 2025, the FDA-cleared-device registry recorded clearance for Innovita Flu A/B under submission K250398.